🇺🇸 FDA
Patent

US 10730834

Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof

granted A61KA61K2300/00A61K31/404

Quick answer

US patent 10730834 (Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof) held by Shuttle Pharmaceuticals, Inc. expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Shuttle Pharmaceuticals, Inc.
Grant date
Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2300/00, A61K31/404, A61K31/573, A61K45/06